Pharming Presents Positive Phase II Leniolisib Data in Genetic PIDs at ESID 2026
Summary
Pharming presented positive Phase II data for leniolisib in genetic PIDs at ESID 2026, showing improvements in spleen volume, lymph nodes, and lung function, with all completers enrolling in a long-term extension study.
Key Events · Product Development and Regulatory · PHAR
-
Phase II Leniolisib Data Presented at ESID
Positive topline data from the Phase II trial of leniolisib in 13 participants with genetic PIDs (CTLA4, SOCS1, NFKB1, FAS variants) were presented at ESID 2026 in Maastricht.
-
Efficacy Across Multiple Measures
Mean spleen volume reduction of 26.4% (n=11), mean lymph node index lesion reduction of 33.7% (n=4), mean DLCO increase of 8.0% in impaired participants (n=7), and liver stiffness improvement in 2 of 3 participants.
-
All Completers Enrolled in Extension
All 12 participants who completed the 20-week study enrolled in the three-year extension study (NCT06990529), indicating tolerability and perceived benefit.
-
Broader Patient Population Opportunity
Estimated prevalence of ~7.5 per million for genetic PIDs and ~39 per million for CVID, versus ~1.5 per million for APDS, suggesting a substantially larger addressable market for leniolisib.
Analysis · PHAR · Life Sciences
Expanded Phase II data for leniolisib in genetic PIDs beyond APDS were presented at ESID 2026, adding new efficacy details and confirming that all 12 completers enrolled in a three-year extension study. The data support a broader label expansion strategy into CVID and other PIDs, which the company estimates represent a patient population roughly 26 times larger than APDS. This matters because leniolisib (Joenja) is Pharming's key growth driver amid declining RUCONEST revenue, and successful expansion into larger PID populations would materially increase the drug's commercial opportunity. The company also flagged topline results from a separate Phase II CVID trial expected in November 2026, a near-term readout that could further validate the broader strategy.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 29.1% of the 1502 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHAR was trading at $9.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $669.7M. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.